Aurealis Therapeutics publishes first study on four-in-one -combination therapy using live lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the company successfully completed an […]
